Novo Nordisk submits diabetes pill for US approval

Novo Nordisk submits diabetes pill for US approval

Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for U.S. approval.

The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a
FILE PHOTO: The logo of Danish multinational pharmaceutical company Novo Nordisk is pictured on the facade of a production plant in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant

COPENHAGEN: Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for U.S. approval.

The Danish drugmaker said on Wednesday it had used a so-called priority review voucher to speed up the anticipated review time of the drug to six months.

The once-daily pill, a key growth hope for the company, belongs to a blockbuster class of treatments known as GLP-1s that stimulate insulin production.

So far, all have been injections and a pill would offer a step-change to overcome the aversion many diabetics have to injections.

Novo Nordisk hopes to launch the pill in 2020.

(Reporting by Stine Jacobsen; Editing by Kirsten Donovan)

Source: Reuters

Bookmark